EE566 Cost-Effectiveness and Budget Impact Analysis of Selective Internal Radiation Therapy Versus Atezolizumab Plus Bevacizumab From a German Statutory Health Insurance Perspective
Abstract
Authors
B Schwander K Klesper S Rossol K Herrmann YF Zoellner